Neurology

New recommendations from the American Academy of Neurology and American Headache Society give providers clearer criteria for preventive migraine therapy.

Researchers assess medication adherence and its associated factors among families of patients with schizophrenia and type 2 diabetes.

Oveporexton, an oral orexin receptor 2 agonist, is the first medicine to restore orexin signaling rather than manage symptoms of the rare sleep disorder.

Pharmacists were asked about their perceived knowledge and attitudes toward patients with Down syndrome.

Subcutaneous lecanemab-irmb can now be self-administered or given by a caregiver from the first dose, eliminating the requirement for an initial in-clinic intravenous infusion.

Patient-centered tools like the Patient's Global Impression of Change scale better assess symptoms, function, quality of life, and treatment effectiveness.

The FDA expands Auvelity for Alzheimer-related agitation, offering a first nonantipsychotic option backed by trials.

FDA approves Wellcovorin for rare FOLR1 cerebral folate deficiency, spotlighting real-world evidence, dosing goals, and key drug-interaction risks.

The FDA approves pitolisant for pediatric cataplexy, offering a rare noncontrolled narcolepsy option with real-world safety data and key interaction tips.

Phase 3 OCEANIC-STROKE shows asundexian cuts recurrent ischemic stroke by 26% on top of antiplatelets, without more major bleeding.

Phase 3 data show oral fenebrutinib slows primary progressive multiple sclerosis disability progression versus ocrelizumab, with early upper-limb gains and a manageable safety profile.

Amid a lack of research on their specific perspectives, women with epilepsy share their experiences with pregnancy and reproductive health.

Novo Nordisk announced results of the evoke and evoke+ phase 3 trials on semaglutide’s use in treating Alzheimer disease progression.

The CDC states that the claim “vaccines do not cause autism” is not evidence based because studies have not ruled out the possibility that infant vaccines cause autism.

Older adults with dementia face significantly higher COVID-19 risks, highlighting the need for targeted health strategies during pandemics.

Pain medication expert Mark Garofoli, PharmD, MBA, BCGP, CPE, CTTS, joined Drug Topics to explore the referenced studies in the Trump Administration’s push to link acetaminophen use with autism.

Mark Garofoli, PharmD, BCGP, CPE, CTTS, also known as “the Pain Guy,” discusses his initial reactions upon learning about the Trump Administration linking acetaminophen use with autism.

As part of this announcement, the administration launches initiatives across the National Institutes of Health, the FDA, and the Center for Medicare & Medicaid Services.

FDA approves Leqembi's subcutaneous formulation, enhancing accessibility for Alzheimer treatment and paving the way for future combination therapies.

Investigators find this association primarily affects female patients when compared with male patients.

Currently, systemic estrogen replacement therapy is contraindicated for women who have a history of ischemic stroke due to the risk of stroke recurrence.

DTC pharmacies offer significant savings on total medication costs for neurological drugs, but out-of-pocket expenses remain high for insured patients.

New research shows metformin's inconsistent neuroprotective effects against Alzheimer disease, challenging its role in diabetes management for cognitive health.

In this retrospective cohort study, researchers investigated the association between formulary coverage for disease-modifying therapies and the potential for MS relapse.

Community pharmacies emerge as key players in early cognitive decline detection, offering vital screening tools and support for at-risk patients.